A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Bristol-Myers Squibb
Arcus Biosciences, Inc.
Pfizer
M.D. Anderson Cancer Center
Enliven Therapeutics
National Cancer Institute (NCI)
Toray Industries, Inc
Ono Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.